Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MEDTRONIC PLC

(MDT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Medtronic : Continuous Rhythm Monitoring Reveals Strong Short-Term Risk Association Between Atrial Fibrilation Episodes and Ischemic Stroke

10/05/2021 | 11:16am EST

DUBLIN - Medtronic plc (NYSE: MDT), the global leader in medical technology, announced the publication of a study demonstrating, through the use of a Medtronic continuous rhythm monitoring device, that atrial fibrillation (AF) is directly and transiently associated with ischemic stroke. The findings were published online(opens new window) on September 29 in JAMA Cardiology.

Stroke impacts more than 795,000 people every year. More than 87% of strokes are ischemic strokes, which occur when vessels that allow blood to flow to the brain are blocked.1 AF is a major risk factor for ischemic stroke, increasing risk of stroke 5-fold compared with those patients who do not have AF.2

This retrospective case-crossover study leveraged data from 466,635 patients included in both the Optum deidentified electronic health record (EHR) and the Medtronic CareLink network databases. Of those, a total of 891 patients with Medtronic cardiovascular implantable electronic devices (CIEDs) capable of continuous rhythm monitoring sustained both an ischemic stroke and received 120 days of continuous monitoring prior to their stroke. A threshold of AF exposure was defined as AF lasting 5.5 hours or more on any given day. Patients were evaluated during a case period that included days 1 to 30 prior to the index stroke and a control period that included days 91 to 120 prior to the event. It was found that 76.5% (682/891) subjects had no AF meeting the threshold in either 30-day period, 16% (143/891) had at least one day with 5.5 hours or more of AF in both periods, and 7.4% (66/891) had informative, discordant rhythm patterns (defined as those that had AF exceeding 5.5 hours in only one period). Key findings were as follows:

Among patients with CIEDs with informative, discordant rhythm patterns, having AF of 5.5 hours or more raised the 30-day risk of ischemic stroke more than three-fold.

Stroke risk was highest within five days of a 5.5 hour or more episode of AF and diminished rapidly thereafter.

A temporal association between AF and stroke was not seen in patients who had been prescribed oral anticoagulants (OACs).

'Overall, these findings significantly underscore traditional thinking that AF is likely a causal risk factor for ischemic stroke as opposed to just a risk marker,' said Daniel Singer, M.D., professor of medicine at Harvard Medical School, professor in the Department of Epidemiology at the Harvard T.H. Chan School of Public Health, and Division of General Internal Medicine at Massachusetts General Hospital. 'The results indicate that prolonged episodes of AF increase stroke risk, but this risk decreases rapidly following the end of the episode. These findings raise the possibility that time-limited anticoagulation for infrequent episodes of AF may be an effective stroke prevention strategy.'

In this study, subjects evaluated had Medtronic CIEDs capable of continuous heart rhythm monitoring via the Medtronic CareLink network, including 114 patients with Medtronic insertable cardiac monitors (ICMs) and 777 with various Medtronic transvenous devices with atrial leads, including implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices, and pacemakers.

'As of late, there has been significant discussion surrounding the temporal relationship of AF episodes to stroke, as well as the use of continuous cardiac monitoring, specifically with ICMs, to detect clinically meaningful AF episodes that may lead to a stroke,' said Rob Kowal, M.D., Ph.D., chief medical officer of the Cardiovascular Diagnostics and Services business, which is part of the Cardiovascular Portfolio at Medtronic. 'This evidence highlights that patients are at highest risk for a stroke within five days of an AF episode that lasts five and a half hours or more. In addition to supporting the use of OACs in this patient population, this study also suggests the value of long-term cardiac monitoring to accurately detect these critical AF episodes.'

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services of the highest quality that deliver clinical and economic value to healthcare consumers and providers around the world.

About Medtronic

Medtronic plc (www.medtronic.com(opens new window)), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contact:

Julia Fuller

Public Relations

T: +1-707-210-2069

Ryan Weispfenning

Investor Relations

T: +1-763-505-4626

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about MEDTRONIC PLC
11/28Vincent Medical Strikes Product Distribution Deal with NYSE-listed Medtronic; Shares Ra..
MT
11/24JPMorgan Adjusts Medtronic's Price Target to $130 from $148, Keeps Overweight Rating
MT
11/24Bernstein Adjusts Medtronic's Price Target to $143 from $148, Keeps Outperform Rating
MT
11/24Stifel Adjusts Medtronic's Price Target to $140 from $145, Keeps Buy Rating
MT
11/24Raymond James Adjusts Medtronic's Price Target to $127 from $142, Keeps Outperform Rati..
MT
11/24Truist Securities Adjusts Medtronic's Price Target to $142 from $148, Keeps Buy Rating
MT
11/24Wells Fargo Adjusts Medtronic's Price Target to $137 From $144, Reiterates Overweight R..
MT
11/24Oppenheimer Adjusts Price Target on Medtronic to $145 From $150, Maintains Outperform R..
MT
11/24Morgan Stanley Adjusts Price Target on Medtronic to $145 From $154, Maintains Overweigh..
MT
11/24Citigroup Adjusts Medtronic's Price Target to $146 From $153, Reiterates Buy Rating
MT
More news
Analyst Recommendations on MEDTRONIC PLC
More recommendations
Financials (USD)
Sales 2022 32 396 M - -
Net income 2022 5 378 M - -
Net Debt 2022 22 296 M - -
P/E ratio 2022 28,4x
Yield 2022 2,26%
Capitalization 149 B 149 B -
EV / Sales 2022 5,30x
EV / Sales 2023 4,90x
Nbr of Employees 90 000
Free-Float 99,8%
Chart MEDTRONIC PLC
Duration : Period :
Medtronic plc Technical Analysis Chart | MDT | IE00BTN1Y115 | MarketScreener
Technical analysis trends MEDTRONIC PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 111,05 $
Average target price 141,32 $
Spread / Average Target 27,3%
EPS Revisions
Managers and Directors
Geoffrey Straub Martha Chairman & Chief Executive Officer
Karen L. Parkhill Chief Financial Officer & Executive Vice President
Laura Mauri Chief Clinical & Regulatory Officer, Senior VP
Richard E. Kuntz Chief Medical & Scientific Officer, Senior VP
Gregory L. Smith Executive VP-Global Operations & Supply Chain
Sector and Competitors
1st jan.Capi. (M$)
MEDTRONIC PLC-5.20%149 347
ABBOTT LABORATORIES14.97%222 592
BECTON, DICKINSON AND COMPANY-2.05%69 611
HOYA CORPORATION27.96%59 428
DEXCOM, INC.60.11%57 374
SARTORIUS STEDIM BIOTECH76.99%53 762